Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that clinical data on Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis, and Cladribine Tablets, an investigational, oral, small ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # Avelumab: 4009, TPS4134, TPS4135, 9036, TPS9105, 3055, TPS3106, 8503, 4514, 4516, 5533, TPS5600, TPS4580, 9508; tepotinib: 4072 - Abstracts featuring Merck compounds span a broad range of cancers, with an emphasis on those which are difficult-to-treat and represent ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Merck obtains CE mark certification for consumables of Gavi(TM) and Geri(TM) as well as for the embryo culture media suite Gems(TM) - Geri(TM) now incorporating innovative software module Geri(TM) Connect + Assess, allowing fertility labs enhanced control and consistency in embryo assessment - ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and U.S. based media - The Fertility Leader Merck receives market authorization from EMA for its advanced GONAL-f® prefilled pen for improved ease-of-use - Patients, nurses and doctors help to innovate and improve the design of a product which has already helped bring over two million babies into the world[1] Merck, a leading science and technology company, today ...
Darmstadt, Germany (ots/PRNewswire) - - Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing - Collaboration allows Merck to provide complementary molecular testing solutions to various laboratory segments - Biocartis' fully automated Idylla(TM) system will enable more clinics to assess RAS ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Despite signs of activity in locally advanced and metastatic pancreatic cancer, two Phase III studies did not meet pre-specified primary endpoints - Merck will focus efforts on more promising candidates in pipeline Merck, a leading science and ...
Darmstadt, Germany (ots/PRNewswire) - - Agreement with BioMarin, a leading company in the treatment of genetic and rare diseases, also includes returning option to develop and commercialize Peg-Pal - Merck to receive upfront payment of EUR 340 million, plus up to EUR 185 million in additional milestones Merck, a ...
Darmstadt, Germany And Manila, Philippines (ots/PRNewswire) - - Merck Philippines joins forces with Health Department and Thyroid Association to put spotlight on health and wellbeing of Filipino women Merck Serono, the biopharmaceutical business of Merck, today announced the launch of a partnership with the Department of Health, Philippines, and the Philippine ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US based media - Global Fertility Alliance will identify and work on improvements of fertility-related laboratory processes Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today ...
Darmstadt, Germany (ots/PRNewswire) - - Global collaboration to extend the portfolio of Merck Serono, a leading company in fertility treatment, in the growing market of fertility technologies to support standardization and improve fertility outcomes - Merck receives global marketing and commercialization rights for ...
Darmstadt, Germany (ots/PRNewswire) - - Hypothyroidism is a disease affecting millions which often goes unrecognized - Symptoms of hypothyroidism often mistaken for other diseases Merck Serono, the biopharmaceutical business of Merck, today announced the support of 7th International Thyroid Awareness Week (ITAW). This year's campaign launched today for ITAW is aimed at ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK based media CHMP recommendation based on results from the Phase IIIb SPARK study Merck Serono, the biopharmaceutical business of Merck, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued ...
Darmstadt, Germany (ots/PRNewswire) - - NOT INTENDED FOR US AND UK BASED MEDIA - ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9086, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591; tecemotide[*]: 3036. - New data on priority candidates from Merck's oncology and immuno-oncology ...
Darmstadt, Germany (ots/PRNewswire) - - NOT INTENDED FOR US AND UK BASED MEDIA - - Evofosfamide is an investigational compound currently in Phase III trials - Advanced pancreatic cancer is second indication to receive FDA fast track designation for evofosfamide Merck, a leading company for innovative and top-quality ...
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer - Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 ...
Darmstadt, Germany And New York (ots/PRNewswire) - Not intended for UK-based media - In the second and third quarters of 2015, Merck and Pfizer will begin co-promoting XALKORI in the United States, Canada, Japan and five European Union countries (France, Germany, Italy, Spain and the United Kingdom) - In the United States and Canada, XALKORI will be co-promoted by EMD ...
Darmstadt, Germany And Barcelona, Spain (ots/PRNewswire) - - Vall d'Hebron, Spain: first hospital to use liquid biopsy RAS biomarker testing technology - Leading research center will use technology to evolve understanding of who will benefit most from targeted treatment to improve patient outcomes - Liquid biopsy ...
Darmstadt, Germany (ots/PRNewswire) - In the news release, "Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan" issued on 13 Feb 2015 06:33 GMT, by Merck over PR Newswire, we are advised by a representative of the company that in the third paragraph ...
Darmstadt, Germany (ots/PRNewswire) - - Not intended for US- and UK-based media - Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science ...
Darmstadt, Germany (ots/PRNewswire) - - Merck Serono's Grant for Growth Innovations (GGI) supports innovative projects to advance understanding in the field of growth - Closing date for entries is January 6, 2015 - Awardees will be announced at the European Society for Paediatric Endocrinology meeting in Barcelona, October 2015 Merck Serono, the biopharmaceutical ...
Darmstadt, Germany (ots/PRNewswire) - - Global winners selected for their unique research projects that have the potential to advance research for the personalized treatment of solid tumors - Winners chosen by a Scientific Steering Committee comprising internationally renowned oncologists and researchers Merck Serono, the biopharmaceutical division of Merck, today ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US- and UK-based media ESMO 2014 Abstract #: Physician biomarker survey: 1080O_PR; Erbitux: CRYSTAL: 541P; LASCCHN: 993PD; DIRECT: 996P; Pipeline: pimasertib: 443O; c-Met: 1333TiP, 450PD, 744TiP, 745TiP; further pipeline: 772P, 507PD, 1235P - New research ...
Darmstadt, Germany (ots/PRNewswire) - - The first grants awarded to coincide with the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting - Investment supports innovative projects for the advancement of science and medical research in the field of growth Merck Serono, the biopharmaceutical division of Merck, today announced the first recipients of the ...
Darmstadt, Germany (ots/PRNewswire) - - Stefan Oschmann appointed Deputy CEO and Vice Chairman of the Executive Board - Belen Garijo appointed new member of the Executive Board - Changes effective from January 1, 2015 Merck today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belen Garijo (54) was appointed to the Executive Board to take over leadership for the ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK based media - Detailed 26-week results of SPARK study presented at SSIEM Annual Symposium - Phenylalanine tolerance significantly increased in children with PKU below 4 years of age, previously shown to be responsive to Kuvan and treated with Kuvan plus a ...
Darmstadt, Germany (ots/PRNewswire) - - First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC) - mMCC is a rare and aggressive skin cancer lacking effective treatments - MSB0010718C is also ...
Darmstadt, Germany (ots/PRNewswire) - - FDA clearance validates Eeva System, which enables in-vitro fertilization (IVF) clinicians to offer the proprietary Eeva Test and further demonstrates commitment by Merck Serono and Auxogyn to bring innovative technologies to the IVF community - Eeva Test first-of-a-kind ...
Darmstadt, Germany (ots/PRNewswire) - - Development and commercialization agreement on blood-based RAS biomarker mutation status test for (metastatic) colorectal cancer (mCRC) - This non-invasive, fast and easy-to-perform diagnostic test is expected to provide a real-time reflection of a patient's RAS mutation status to help guide clinical decision making in mCRC Merck ...